Barclays’s Definium Therapeutics DFTX Stock Holding History

Barclays’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.37M	Buy	50,296 +10,613	+27%	+$262K	﹤0.01%	2247
2026 Q1	$750K	Sell	39,683 -143,940	-78%	-$2.44M	﹤0.01%	2933
2025 Q4	$2.46M	Buy	183,623 +33,018	+22%	+$409K	﹤0.01%	2783
2025 Q3	$1.78M	Sell	150,605 -24,628	-14%	-$230K	﹤0.01%	2964
2025 Q2	$1.14M	Buy	175,233 +55,660	+47%	+$366K	﹤0.01%	3253
2025 Q1	$700K	Sell	119,573 -35,861	-23%	-$257K	﹤0.01%	3315
2024 Q4	$1.08M	Buy	155,434 +19,336	+14%	+$133K	﹤0.01%	3329
2024 Q3	$774K	Buy	136,098 +91,271	+204%	+$635K	﹤0.01%	3523
2024 Q2	$323K	Buy	44,827 +35,680	+390%	+$312K	﹤0.01%	3304
2024 Q1	$86K	Hold	9,147	–	–	﹤0.01%	4484
2023 Q4	$33.5K	Hold	9,147	–	–	﹤0.01%	4823
2023 Q3	$28.6K	Hold	9,147	–	–	﹤0.01%	4073
2023 Q2	$32.7K	Hold	9,147	–	–	﹤0.01%	4010
2023 Q1	$29K	Hold	9,147	–	–	﹤0.01%	4581
2022 Q4	$20.1K	Sell	9,147 -78	-0.8%	-$217	﹤0.01%	4811
2022 Q3	$32K	Buy	9,225 +7,705	+507%	+$74K	﹤0.01%	3915
2022 Q2	$15K	Sell	1,520 -1,965	-56%	-$24.9K	﹤0.01%	4502
2022 Q1	$58K	Buy	+3,485	New	+$60.5K	﹤0.01%	4055

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Barclays's DFTX Position: Q2 2026 in Review

Barclays increased its Definium Therapeutics (DFTX) stake by 27% in Q2 2026, buying an estimated $262K and bringing the position to 50,296 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2247.

Barclays first reported a position in DFTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.46M in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Barclays held 50,296 shares of Definium Therapeutics worth $2.37M as of Q2 2026.
Barclays bought 10,613 Definium Therapeutics shares in Q2 2026, an estimated $262K.
Definium Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2247 holding.
Barclays first reported a position in Definium Therapeutics in Q1 2022 and has held it in 18 quarters since.
Barclays's Definium Therapeutics position peaked at $2.46M in Q4 2025.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.